Summary:
ZuvaSyntha is developing proprietary renewable manufacturing routes to industrial chemicals from low cost feedstocks such as syngas and methanol.
Its lead program…
read moreKeeping operational in COVID: pandemic planning and resilience
The challenges of running a start-up through a pandemic: Hiring
The Role of Public-Private Partnerships in the Future of Fusion Energy
MicrofluidX raises £1.4m in seed funding to develop novel cell therapy bioprocessing technology
New analysis confirms value of UKI2S investing public money to commercialise public science
Corporate communications in the COVID-19 crisis
How to build a start-up: Launching early stage science companies
UKI2S, Catapult Ventures and Jonathan Milner invest £500K in gene modulation newcomer Pencil Biosciences
Spin out secures £1.1M for ground-breaking ‘supercharged’ cell therapies to treat solid tumours
Rapid test for gonorrhoea and chlamydia to be developed by University of Birmingham spinout
Expert Interview with Gilad Gershon: Selecting the right talent for your start-up
Summary:
ZuvaSyntha is developing proprietary renewable manufacturing routes to industrial chemicals from low cost feedstocks such as syngas and methanol.
Its lead program…
read more